...
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements
【24h】

Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements

机译:化学敏感性由SDF-1 / CXCR4和SDF-1 / CXCR7轴差异调节,急性淋巴细胞白血病具有MLL基因重排

获取原文
获取原文并翻译 | 示例

摘要

Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL + ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGF beta 1 both of which are produced from bone marrow stromal cells synergistically induced MLL + ALL cells into chemo-resistant quiescence, and that treatment of MLL + ALL cells with inhibitors against FLT3 and/or TGF beta 1 receptor partially but significantly converts them toward chemosensitive. In the present study, we showed that MLL + ALL cells expressed CXCR4 and CXCR7, both receptors for the same chemokine stromal cell derived factor-1 (SDF-1), but their biological events were differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes and particularly exerted an opposite effect for determining chemo-sensitivity of MLL + ALL cells; enhancement via the SDF-1/CXCR4 axis vs. suppression via the SDF-1/CXCR7 axis. Because cytosine-arabinoside-induced apoptosis of MLL + ALL cells was inhibited by pretreatment with the CXCR4 inhibitor but rather accelerated by pretreatment with the CXCR7 inhibitor, an application of the CXCR7 inhibitor may become a good treatment option in future for MLL + ALL patients. MLL + ALL has a unique gene profile distinguishable from other types of ALL and AML, and should be investigated separately in responses to biological active agents including chemokine inhibitors.
机译:尽管化疗的最近进展明显改善了急性淋巴细胞白血病(全部)的结果,但婴儿均具有MLL基因重排(MLL +全部)是化疗的难治性。我们已经表明,特异性细胞因子FLT3配体和TGFβ1的两者都是由骨髓基质细胞协同诱导的MLL +所有细胞产生的化学抗静态,并且将MLL +与FLT3和/或TGF的抑制剂治疗所有细胞的处理β1受体部分但显着将它们转化为化学化学。在本研究中,我们表明MLL +所有细胞表达CXCR4和CXCR7,两个受体对于相同的趋化因子基质细胞衍生因子-1(SDF-1),但它们的生物事件被SDF-1 / CXCR4差异调节SDF-1 / CXCR7轴特别施加相反的效果,用于确定MLL +所有细胞的化学敏感性;通过SDF-1 / CXCR4轴增强通过SDF-1 / CXCR7轴的抑制。由于CXCR4抑制剂的预处理,通过预处理通过对CXCR7抑制剂预处理来抑制胞嘧啶 - 阿拉伯苷诱导的凋亡,因此通过预处理加速,CXCR7抑制剂的应用可能是MLL +所有患者的未来良好的治疗选择。 MLL +全部具有独特的基因曲线,可区分其他类型的全部和AML,并且应在对包括趋化因子抑制剂的生物活性剂的反应中分开进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号